Risk of Cardiac Valve Regurgitation with Dopamine Agonist Use in Parkinson’s Disease and Hyperprolactinemia

Aug-10

Cardiovascular Neurology Pharmacoepidemiology

AUTHORS : Gianluca Trifirò, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, 1, Consolare Valeria Street, 98125, Messina, Italy AND Department of Medical Informatics, Erasmus Medical Centre, Rotterdam, Doctor Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands – Email: trifirog@unime.it – Profile: https://www.unime.it/it/persona/gianluca-trifir%C3%B2

JOURNAL : Pharmacoepidemiology and Drug Safety

REFERENCE: 19(S1):275-276

DOI : 10.1002/pds.2019

Risk of Cardiac Valve Regurgitation with Dopamine Agonist Use in Parkinson’s Disease and Hyperprolactinemia

More publications

Ten years preceding a diagnosis of neurodegenerative disease in Europe and Australia: medication use, health conditions, and biomarkers associated with Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis

Association Between Type 2 Diabetes Onset Age and Risk of Cardiovascular Disease and Mortality: Two Cohort Studies from United Kingdom and Hong Kong

Prodromal Parkinson’s disease and subsequent risk of Parkinson’s disease and mortality